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The interaction of nutrients with the small intestinemodulates postprandial cardiovascular
function. Rapid small intestinal nutrient delivery may reduce blood pressure markedly,
particularly in patients with type 2 diabetes (T2DM). Postprandial hypotension occurs
in ∼30% of patients with longstanding T2DM, but there is little information about the
cardiovascular effects of different macronutrients. We compared the blood pressure and
heart rate responses to standardized intraduodenal glucose and fat infusions in T2DM.
Two parallel groups, including 26 T2DM patients who received intraduodenal glucose
infusion and 14 T2DM patients who received intraduodenal fat, both at 2 kcal/min over
120min, were compared retrospectively. Blood pressure and heart rate were measured
at regular intervals. Systolic blood pressure was stable initially and increased slightly
thereafter in both groups, without any difference between them. Diastolic blood pressure
decreased in response to intraduodenal glucose, but remained unchanged in response
to lipid, with a significant difference between the two infusions (P = 0.04). Heart rate
increased during both intraduodenal glucose and lipid infusions (P < 0.001 each), and
the increment was greater in response to intraduodenal fat than glucose (P = 0.004). In
patients with T2DM, intraduodenal fat induced a greater increase in heart rate, associated
with a diminished reduction in blood pressure, when compared with isocaloric glucose.
The macronutrient composition of meals may be an important consideration in T2DM
patients with symptomatic postprandial hypotension.
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INTRODUCTION
Exposure of the small intestine to ingested nutrients is associated with a substantial increase in
splanchnic blood flow and a decrease in peripheral blood volume, which may lead to a reduction
in blood pressure and, in some cases, postprandial hypotension (a fall in systolic blood pressure of
≥20 mmHg within 2 h of a meal) (1). The latter occurs frequently in patients with type 2 diabetes
(T2DM), and predisposes to syncope, fall and stroke (1). The rate of gastric emptying (or small
intestinal nutrient delivery) is a key determinant of the cardiovascular responses to meals/nutrients
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in both health and T2DM (1, 2), such that pharmacological
or dietary interventions that slow gastric emptying diminish
the hypotensive response to meals (3). However, it remains
controversial as to whether the gut-provoked changes in
cardiovascular function are also dependent on the type of
macronutrient. For example, in healthy older individuals, oral
carbohydrate, but not fat or protein, induced a hypotensive
response (4), whereas intraduodenal infusion of glucose, fat and
protein (∼3 kcal/min) was reported to reduce blood pressure
and increase heart rate comparably, although the timing of
these changes differed slightly between them (5). While the use
of intraduodenal, as opposed to oral, nutrient administration
ensures that the small intestinal exposure to each nutrient is
standardized, the rate of intraduodenal infusion employed in
the previous studies has approximated the upper-end of the
physiological range of gastric emptying (i.e., 1–4 kcal/min) (6),
which may limit the capacity to discriminate the effects of
different nutrients. Moreover, the comparative effects of different
nutrients on blood pressure and heart rate have not been
investigated in patients with T2DM.
In the current study, we compared the blood pressure and
heart rate responses to intraduodenal glucose and fat infusions
at a rate of 2 kcal/min in patients with T2DM.
METHODS AND MATERIALS
Participants
Forty participants with type 2 diabetes managed by diet or
metformin monotherapy (500–2,000 mg/day, stable for > 3
months) were recruited from the community by advertisement
for studies evaluating nutritional and/or pharmacological
therapies for diabetes in our center. Twenty-six participants
received an intraduodenal glucose infusion (7, 8) and 14
participants received an intraduodenal lipid infusion (9)
following identical procedures after providing written informed
consent (Table 1). We have previously reported the outcomes
relating to blood glucose and gut hormones. We now report
the data on blood pressure and heart rate collected from these
TABLE 1 | Subject characteristics.
Glucose Lipid P-value
Gender (male/female) 21/5 9/5 0.3
Age (years) 65 ± 2.3 68 ± 2.4 0.1
BMI (kg/m2 ) 30.3 ± 1.5 30.7 ± 1.3 0.8
HbA1c (%) 6.4 ± 0.1 6.7 ± 0.2 0.1
HbA1c (mmol/mol) 46.7 ± 1.1 49.9 ± 2.1 0.1
Duration of known diabetes (years) 4.5 ± 1 6.5 ± 1.5 0.2
Fasting blood glucose (mmol/l) 7.7 ± 0.3 7.9 ± 0.7 0.8
Use of hypotensive medication 7/26 3/14 0.2
Basal systolic blood pressure (mmHg) 131.4 ± 3 136.1 ± 5.6 0.4
Basal diastolic blood pressure (mmHg) 75 ± 1.6 72.3 ± 2.4 0.3
Basal heart rate (beats/min) 58.1 ± 1.7 61.6 ± 2.9 0.3
Data are mean values ± SEM.
studies. None had impaired liver or renal function, significant
gastrointestinal disease or prior gastrointestinal surgery, or
diabetic microvascular complications, including autonomic
dysfunction as assessed using standardized cardiovascular reflex
tests. All antihypertensive medications were withheld for 24 h
prior to the study. The protocols were approved by the Royal
Adelaide Hospital Human Research Ethics Committee.
Protocol
Blood pressure and heart rate were evaluated on a single study
visit. All participants refrained from strenuous physical activity
for 24 h before the study. After a standardized evening meal
(McCain beef lasagne, Victoria, Australia) at ∼1,900 h and an
overnight fast, participants attended the laboratory at 0800 h.
A multi-lumen silicone catheter (Dentsleeve International Ltd,
Mui Scientific, Ontario, Canada) was inserted transnasally
and allowed to pass into the duodenum by peristalsis, as
described (5). An infusion port opened 12 cm beyond the
pylorus. Commencing at t = 0min, either glucose or lipid
(20% Intralipid, consisting of long-chain triglycerides; Fresenius
Kabi AB, Sweden) was infused at 2 kcal/min over 120min
(t = 0–120min) while the participant was lying supine. Systolic
and diastolic blood pressure and heart rate were measured
regularly (glucose infusion group: every 5min; lipid infusion
group: every 3min) from 60min before starting infusion using
an automatic sphygmomanometer (GE Healthcare, Milwaukee,
WI, United States). Mean blood pressure and heart rate every
15min were reported. Data on heart rate during intraduodenal
lipid infusion were only available for nine patients only due to
technique issues. Baseline blood pressure and heart rate were
calculated as an average of the measurements obtained 15min
prior to intraduodenal infusion.
Statistical Analysis
Demographic data in the two groups were compared using
unpaired Student’s t-tests after confirming their normality of
distribution, with the exception that the proportions of gender
and use of antihypertensive medication were compared using
Fisher’s exact test. Blood pressure and heart rate responses to
intraduodenal infusions were evaluated using two-way repeated
measures ANOVA, with treatment and time as factors. Post hoc
comparisons, adjusted for multiple comparisons by Bonferroni’s
correction, were performed if ANOVAs revealed significant
interactions. Analyses were performed using Prism 8.0 (La
Jolla, CA, United States). P-value less than 0.05 was considered
statistically significant. Data are expressed as means± SEM.
RESULTS
All participants tolerated the study well and none exhibited a fall
in systolic blood pressure ≥20 mmHg during the study. Baseline
characteristics, including age, sex, BMI, HbA1c, fasting blood
glucose, use of antihypertensive medication, fasting systolic and
diastolic blood pressure and heart rate, were well matched
between the two groups (Table 1). During intraduodenal
infusion, systolic blood pressure remained relatively stable for
the first 60min, and increased slightly thereafter in both groups
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FIGURE 1 | Change in systolic blood pressure (A), diastolic blood pressure (B), and heart rate (C) in response to intraduodenal glucose or fat infusion at 2 kcal/min
(t = 0–120 min) in type 2 diabetes. Repeated-measures ANOVA was used to determine statistical difference. Results of ANOVA are reported as P-values for
differences over treatment, difference by time and differences due to treatment by time interaction. Post hoc comparisons were adjusted by Bonferroni’s correction. If
ANOVA results were significant. *P < 0.05 for each. Data are mean values ± SEM.
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(time effect: P < 0.001 during glucose, and P = 0.14 during
lipid, infusion), without significant difference between them
(Figure 1A). Diastolic blood pressure decreased by ∼5 mmHg
within the first 60min followed by a slow recovery during glucose
infusion (time effect: P < 0.001), but remained unchanged
during lipid infusion (time effect: P = 0.61), such that the
reduction in diastolic blood pressure was greater in response
to intraduodenal glucose than lipid (treatment effect: P = 0.04)
(Figure 1B). Heart rate increased progressively within the first
60min and plateaued thereafter during both infusions [time
effect: P < 0.001 for each). The increment in heart rate was
greater in response to intraduodenal lipid than glucose (P= 0.004
for treatment effect; P < 0.001 for treatment by time interaction,
with significant differences between t= 60–105min (P< 0.05 for
each)] (Figure 1C).
DISCUSSION
In patients with relatively well-controlled, uncomplicated T2DM,
we observed a reduction in diastolic blood pressure in response
to intraduodenal glucose infusion at a rate of 2 kcal/min, but
not to an isocaloric fat infusion, probably due to its greater
effect to increase heart rate. These observations suggest that the
macronutrient composition of a meal may have a major impact
on postprandial cardiovascular function in T2DM.
In contrast to previous observations made in healthy older
participants during intraduodenal infusion of glucose and fat at
a higher rate (∼3 kcal/min) (5), there were minimal changes
in systolic blood pressure in response to intraduodenal glucose
and lipid infusion in the present study. This is likely to reflect
that the hypotensive response to enteral nutrients is subject
to the rate of small intestinal nutrient delivery (2), and that
intraduodenal infusion of glucose and lipid at a rate of 2
kcal/min may not be sufficient to induce a marked reduction
in systolic blood pressure (2). In addition, we observed a
greater increase in heart rate during intraduodenal fat than
glucose infusion, which may account for the observed absence
of reduction in diastolic blood pressure. The apparent lack of
any difference in the blood pressure and heart rate responses to
glucose and fat observed previously may reflect near maximal
changes in blood pressure and heart rate at the higher rate of
nutrient infusion.
The mechanisms underlying the differences in the blood
pressure and heart rate responses to intraduodenal glucose
and lipid remain to be defined, but are unlikely to be
related to peripheral glucose and insulin levels (1). We have
shown that intraduodenally administered fat (at 2 kcal/min)
is more potent than glucose at stimulating the secretion of
the “incretin” hormones glucagon-like peptide-1 (GLP-1) and
glucose-dependent insulinotropic polypeptide (GIP) (10), which
have the capacity to modulate cardiovascular function in
humans. For example, administration of both exogenous GLP-
1 and GLP-1 receptor agonists has been shown to increase
heart rate and attenuate the hypotensive response to an oral
glucose or intraduodenal glucose infusion in both healthy
subjects and patients with T2DM (3, 11–13). Conversely,
blockade of endogenous GLP-1 signaling by the GLP-1 receptor
antagonist, exendin (9–39), diminishes the heart rate increase
in response to intrajejunal glucose infusion in patients with
T2DM (14). While the role of endogenous GIP signaling in
the regulation of blood pressure and heart rate has not been
investigated in detail, exogenous GIP has been reported to
decrease blood pressure and increase heart rate in individuals
with impaired glucose tolerance (15). In addition, differences
in the digestive requirements between glucose and fat may
be of relevance. In support of this concept, inhibition of
lipid digestion by orlistat was shown to attenuate the heart
rate response to intraduodenal fat infusion (at 3 kcal/min)
in healthy older humans, although blood pressure was not
affected (16).
In interpreting our findings, several limitations should be
noted. First, our model of infusing either glucose or fat directly
into the duodenum is, by definition, non-physiological, and
does not allow us to evaluate the contribution of gastric
factors to the regulation of postprandial blood pressure and
heart rate. However, it is ideal to differentiate the blood
pressure and heart rate changes mediated by the small
intestine in response to glucose and fat, by standardizing
the delivery of nutrients into the small intestine. Bypassing
the stomach eliminated the potential influence of gastric
emptying on the postprandial blood pressure and heart rate
responses (17). Moreover, it circumvented the impact of
differing degrees of gastric distension arising from variations
in the rate of gastric emptying between individuals (18, 19).
Second, we did not measure cardiac hemodynamics, cardiac
output and muscle sympathetic activity, which would have
provided a more comprehensive characterization of postprandial
cardiovascular function. Third, the sample sizes were relatively
small; however, the findings appeared clear-cut. Finally, the
T2DM patients were relatively well-controlled and had no
evidence of cardiovascular autonomic dysfunction, which may in
part have accounted for the fact that the falls in blood pressure
were modest. Evaluation of patients with more advanced T2DM,
particularly in those prone to postprandial hypotension, would
be of interest.
In summary, when administered at identical
energy loads, fat increases heart rate more than
glucose, associated with a diminished reduction
in blood pressure, in patients with relatively well-
controlled, uncomplicated T2DM. These observations
highlight the distinct impact of different nutrients on
postprandial cardiovascular function and suggest that
the macronutrient composition of meals may be an
important consideration in T2DM patients with symptomatic
postprandial hypotension.
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